Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic acid for treatment of idiopathic nephrotic syndrome (pilot study)
2016-003198-17Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valproic acid in Idiopathic nephrotic syndrome (INS), focal segmental glomerulosclerosis (FSGS) and nephrosis, sponsored by UZ Brussel. Primary endpoint: Complete remission rate. Started Sep 2016; status: completed.
02
Drugs
valproic acid
03
Conditions
Idiopathic nephrotic syndrome (INS)focal segmental glomerulosclerosis (FSGS)nephrosis
Beyond the preview
Go deeper on 2016-003198-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003198-17.